Cosentyx TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: secukinumab
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 150 mg powder for injection vialWhat this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage),COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, powder for
- Subcutaneous
- Colourless 6 mL glass vials, chlorobutyl rubber stopper with fluorocarbon layer on the product side, aluminum cap with plastic flip off lid
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Store in Original Container
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 1 vial pack
- 2 vials pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 150 mg powder for injection vialWhat this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage),COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, powder for
- Subcutaneous
- Colourless 6 mL glass vials, chlorobutyl rubber stopper with fluorocarbon layer on the product side, aluminum cap with plastic flip off lid
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Store in Original Container
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 1 vial pack
- 2 vials pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 150 mg/1 mL solution for injection in prefilled syringeWhat this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage) COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear, colourless-slightly yellow liquid in pre-assembled 1 mL glass syringe, with needle, needle shield, plunger, & safety device in blister
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Store in Original Container
- See Product information for shelf life
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 1 syringe pack
- 2 syringes pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 150 mg/1 mL solution for injection in prefilled penConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage),COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Pen containing a clear, colourless-slightly yellow liquid in 1 mL glass syringe, with seal bridges, cap, and label.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Store in Original Container
- See Product information for shelf life
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 1 pen pack
- 2 pens pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on August, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 150 mg/1 mL solution for injection in prefilled penConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage),COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Pen containing a clear, colourless-slightly yellow liquid in 1 mL glass syringe, with seal bridges, cap, and label.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Store in Original Container
- See Product information for shelf life
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 1 pen pack
- 2 pens pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on August, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 150 mg/1 mL solution for injection in prefilled syringeWhat this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage) COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear, colourless-slightly yellow liquid in pre-assembled 1 mL glass syringe, with needle, needle shield, plunger, & safety device in blister
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Store in Original Container
- See Product information for shelf life
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 1 syringe pack
- 2 syringes pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 75 mg/0.5 mL solution for injection pre-filled syringeConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage),COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear to opalescent, colourless to slightly yellowish solution for injection
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- Pack of 1 pre-filled syringe pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 300 mg/2 mL solution for injection pre-filled syringeWhat this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage),COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear to opalescent, colourless to slighlty yellowish solution for injection
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- Pack of 1 pre-filled syringe pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: COSENTYX secukinumab (rch) 300 mg/2 mL solution for injection pre-filled penConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
Plaque psoriasis,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.,Axial spondyloarthritis (axSpA) with or without radiographic damage,Ankylosing spondylitis (axSpA with radiographic damage),COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.,Non-radiographic axial spondyloarthritis (axSpA without radiographic damage),COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.,Juvenile Idiopathic Arthritis (JIA),Enthesitis-Related Arthritis (ERA),Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Juvenile Psoriatic Arthritis (JPsA),Cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.,Hidradenitis Suppurativa (HS),COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear to opalescent, colourless to slighlty yellowish solution for injection
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- Pack of 1 pre-filled pen pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient secukinumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
